Alcon refiles NDA for Patanase
This article was originally published in Pharmaceutical Approvals Monthly
Executive Summary
After pulling its Patanase (olopatadine) nasal spray NDA in November 2005, Alcon resubmits the application with an amendment to modify its formulation. The amendment includes six-month data from an agreed-upon study requested by FDA to remove or reduce one of the inactive ingredients (1Pharmaceutical Approvals Monthly November 2005, In Brief). The pending NDA seeks approval of the ophthalmic solution, which has the same active ingredient as the firm's Patanol ophthalmic solution, for treatment of allergic rhinitis...
You may also be interested in...
Alcon Patanase chemistry issues
Alcon is testing a modified formulation of its pending olopatadine nasal spray Patanase after receiving "correspondence from…FDA requiring that the current formulation of the drug be modified to reduce or remove one of the inactive ingredients it contains before Patanase nasal spray can be approved," Alcon says Nov. 7. The company previously had indicated it expected such a request. The Patanase NDA for seasonal allergic rhinitis was submitted in December 2004; Patanase contains the same active ingredient as the firm's allergic conjunctivitis treatment Patanol...
As Casgevy, Lyfgenia Launches Proceed, CRISPR And bluebird bio CEOs Reassure
The CEOs of bluebird bio and CRISPR Therapeutics hope to inspire investor confidence that their gene-based therapies for sickle cell disease and beta thalassemia will be widely reimbursed in the US and EU.
Japan Regulatory Update: Revised Law Widens RWD Scope, Price Revisions/Listings
Japan now allows pseudonymized personal data for medical use under a licensing system for wider use of real-world data. Meanwhile, a national cost-effectiveness assessment scheme has slashed reimbursement prices for Lagevrio and Kerendia, and Alexion’s Voydeya has been added to the reimbursement tariff.